Clinical trials: Heart Transplant Recipients
Lung Transplant Infection, Heart Transplant Infection
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
The success of transplantation is significantly hindered by the lack of sufficient number of available donors. Many potential donor organs cannot be utilized in clinical transplantation because donors have chronic viral…
- Conditions
- Lung Transplant Infection, Heart Transplant Infection, Kidney Transplant Infection, Kidney Pancreas Infection
- Trial name
- NCT04017338
- Testing
- Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Jordan Feld
Heart Transplantation
L-arginine Supplementation and Exercise; L-arginine Supplementation and Renal Function
exercise capacities are still altered after heart transplantation partly due to peripheral endothelial dysfunction cyclosporin-induced renal dysfunction may be due to renal endothelial dysfunction and can be reversed in an animal…
- Trial name
- NCT00213915
- Testing
- 12 g of L-arginine glutamate during 6 weeks twice a day
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Lung Transplant
CIS001 Extension Study of Cyclosporine Inhalation Solution
This trial is a longterm follow up of a phase III study of inhaled cyclosporine for the prevention of chronic rejection in lung transplant recipients.
- Trial name
- CIS002 (NCT00938236)
- Testing
- Cyclosporine Inhalation Solution (CIS)
- Where
- 16 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- APT Pharmaceuticals, Inc.
Heart Transplant, Cardiovascular Disease
Randomized Trial of SGLT2i in Heart Transplant Recipients
Heart transplant (HTx) is an established therapy for advanced heart disease that restores quality of life and improves survival.
- Conditions
- Heart Transplant, Cardiovascular Disease, Kidney Disease
- Trial name
- NCT06625073
- Testing
- Empagliflozin
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- VA Office of Research and Development
Heart Transplant Rejection, Immune Suppression
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR)…
- Conditions
- Heart Transplant Rejection, Immune Suppression, Pediatric Heart Transplant, Medication Nonadherence
- Trial name
- NCT05732779
- Testing
- DOT intervention
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Florida
Heart Transplantation
Brachial Artery t-PA Release in Heart Transplant Recipients
Bradykinin stimulates t-PA release from intact vessels, but not from endothelial cells in culture. It has been proposed that the nerves of blood vessels are the source of bradykinin stimulated t-PA release.
- Trial name
- P1A3C (NCT00780637)
- Testing
- Bradykinin
- Where
- United States
- Sponsor
- Vanderbilt University
Heart Transplantation, Lung Transplantation
Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®
Comparison of tacrolimus blood levels in adults who have received a transplant and are taking either Prograf or Advagraf anti-rejection therapy immediately following surgery.
- Conditions
- Heart Transplantation, Lung Transplantation, Pancreas (Including SPK) Transplantation
- Trial name
- NCT01332201
- Testing
- Advagraf, Prograf
- Where
- 8 sites in Austria, Belgium and 4 more
- Volunteers
- 17 people
- Sponsor
- Astellas Pharma Inc
Disorder Related to Cardiac Transplantation
Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation
This study investigated whether initiation of everolimus together with reduction of calcineurin inhibitors (CNI) in maintenance heart or lung transplant patients with renal impairment would improve renal function.
- Trial name
- NOCTET (NCT00377962)
- Testing
- Everolimus, Mycophenolic acid (MPA)/azathioprine (AZA), Calcineurin inhibitors (CNI)
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 282 people
- Sponsor
- Novartis Pharmaceuticals
Heart Transplant Recipients
Autonomic Cardiovascular Control After Heart Transplantation
The purpose of this prospective study is to investigate denervation (ie. surgical cutting of autonomic nerves) and re-innervation (ie. growth of autonomic nerves) in heart transplant recipients. More specifically, we focus on: 1.
- Trial name
- AccHeart (NCT01759966)
- Where
- Norway
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Heart Transplant Rejection
Heartsbreath Test for Heart Transplant Rejection
The purpose of this study is to demonstrate and validate a breath test for detection of biomarkers of heart transplant rejection (Grade 2R heart transplant).
- Trial name
- Heartsbreath (NCT01397812)
- Testing
- BreathScanner 1.0, BreathLink
- Where
- 5 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Menssana Research, Inc.
Heart Transplant Recipients
Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Iron deficiency is prevalent in heart transplant recipients, and may be associated with reduced functional capacity. The IronIC trial is designed to assess the effect of intravenous iron isomaltoside on exercise capacity, muscle…
- Trial name
- IronIC (NCT03662789)
- Testing
- Iron Isomaltoside 1000
- Where
- Norway
- Volunteers
- 102 people
- Sponsor
- Oslo University Hospital
Microsporidiosis Intestinal, Heart Transplant Infection
Intestinal Microsporidiosis in French Heart Transplant Recipients (CARMIC)
The investigators propose to carry out a national retrospective study to collect epidemiological, biological, clinical and therapeutic data on microsporidiosis among heart transplant patients.
- Trial name
- CARMIC (NCT06986980)
- Where
- France
- Volunteers
- 39 people
- Sponsor
- University Hospital, Clermont-Ferrand
Heart Transplantation, Liver Transplantation
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
The aims of this 3-year randomized, single-blinded clinical trial are to compare the effect of high and low feedback about performance on the bedside exercise device in heart or liver transplantation recipients during the…
- Trial name
- NCT01705015
- Testing
- direct feedback about exercise
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- National Taiwan University Hospital
Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
Impact of Allo- and Autoantibodies on Chronic Cardiac Allograft Function
This is a multi-center, prospective, single cohort, observational study of pediatric heart transplant recipients designed to determine the impact of preformed versus de novo human leukocyte antigen (HLA) donor-specific antibodies…
- Trial name
- NCT02752789
- Where
- 9 sites in United States, Canada
- Volunteers
- 407 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Transplant
Belatacept in Heart Transplantation
This is a phase 2, prospective, multi-center, open-label clinical trial. Sixty-six (66) primary heart transplant recipients will be randomized (1:2) to receive either standard-of-care, tacrolimus-based immunosuppression, or a…
- Trial name
- NCT06478017
- Testing
- Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Heart Transplantation
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
Heart transplant patients on a standard care regimen of CNI, MMF, and corticosteroids will enter the study 4-6 weeks post-transplant.
- Trial name
- NCT00121784
- Testing
- mycophenolate mofetil [CellCept]
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Heart Failure, Ischemic Heart Disease
Acute Effect of Strength Training on Blood Pressure in Cardiac Patients
Moderate and heavy strength training exercise and the acute blood pressure rise in cardiac patient, how high?
- Conditions
- Heart Failure, Ischemic Heart Disease, Heart Transplant Recipients
- Trial name
- NCT01912248
- Testing
- strength training
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- Christian Dall
Cardiac Allograft Vasculopathy
Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy
The CART Pilot study was designed to provide preliminary observations (about performance and safety) and generate hypotheses for future studies .
- Trial name
- CART (NCT02377648)
- Testing
- Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)
- Where
- 10 sites in Italy, Netherlands
- Volunteers
- 34 people
- Sponsor
- Universita di Verona
Cardiac Allograft Vasculopathy
Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Many patients with end-stage heart failure, a condition in which the heart fails to pump enough blood to support the body's other organs, are fortunate enough to receive a heart transplant.
- Trial name
- NCT05373108
- Testing
- Macitentan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, Los Angeles
Cardiac Allograft Vasculopathy
Noninvasive Evaluation of Cardiac Allograft Vasculopathy
Abnormal peripheral endothelial function and alterations in circulating biomarkers that are associated with endothelial activation and inflammation correlate with angiographic evidence of cardiac allograft vasculopathy, defined…
- Trial name
- CAVII (NCT01305382)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Minnesota